Borboletas (Lepidoptera: Hesperioidea e papilionoidea) de val de serra, região central do rio grande do sul, Brasil

The butterfly fauna of the Atlantic Forest Biome is reasonably well-known up to the southern limit of its distribution. However, there are knowledge gaps nearby the central region of Rio Grande do Sul State, whose forest areas are considered priorities for biological conservation. This study investigated the butterfly assemblage of a riparian fragment in an ecotone area between Mixed Ombrophilous Forest and Seasonal Decidous Forest, in Itaara municipality. From September 2005 to September 2006, after 105 net-hours through active search sampling, 877 butterflies were registered representing 104 species. Three more species were registered posteriorly, increasing total richness to 107. The most abundant species were the Nymphalidae Hermeuptychia hermes (Fabricius, 1775), Yphthimoides celmis (Godart, [1824]), Agraulis vanillae maculosa (Stichel, [1908]), Tegosa claudina (Eschscholtz, 1821) and Vanessa braziliensis (Moore, 1883). One new record for the State and four new ones for the central region were registered besides the southern endemic Papilionidae Euryades corethrus (Boisduval, 1836) and the Lycaenidae Arcas ducalis (Westwood, 1852), considered indicator of Atlantic forest preserved areas. Due to the representativeness of the registered fauna, it is suggested the increase of conservation efforts in the area and stimulation of new ecological studies with the local biodiversity

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Seismic stratigraphy and evolution of the Raggatt Basin, southern Kerguelen Plateau

Six major seismic stratigraphic sequences in the Raggatt Basin on the southern Kerguelen Plateau overlie a basement complex of Cretaceous or greater age. The complex includes dipping reflectors which were apparently folded and eroded before the Raggatt Basin developed. The seismic stratigraphic sequences include a basal unit F, which fills depressions in basement; a thick unit, E, which has a mounded upper surface (volcanic or carbonate mounds); a depression-filling unit, D; a thick unit C which is partly Middle to Late Eocene; and two post-Eocene units, A and B, which are relatively thin and more limited in areal extent than the underlying sequences. A mid or Late Cretaceous erosional episode was followed by subsidence and basin development, interrupted by major erosion in the mid Tertiary. Late Cenozoic sedimentation was affected by vigorous ocean currents